• Gedeon Richter plc, of Budapest, Hungary, and Forest Laboratories Inc., of New York, reported top-line results from a Phase III trial of cariprazine (RHG-188), an antipsychotic agent, in patients with acute mania associated with bipolar I disorder. For the primary endpoint, the Young Mania Rating Scale, data showed cariprazine-treated patients experienced significant improvements in symptoms compared to those in the placebo arm, observed as early as day five of treatment and at each subsequent time point studied.